This study compared (68)Gallium-prostate-specific-membrane-antigen based Positron-emission-tomography ((68)Ga-PSMA-PET) and (99metastable)technetium-3,3-diphospho-1,2-propanedicarbonacid ((99m)Tc-DPD-SPECT) in performing skeletal staging in prostate cancer (PC) patients and evaluated the additional value of the information from low-dose-computed tomography (CT).
In this retrospective study, 54 patients who received (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT within 80 days were extracted from our database. Osseous lesions were classified as benign, malignant or equivocal. Lesion, region and patient based analysis was performed with and without CT fusion. The reference standard was generated by defining a best valuable comparator (BVC) containing information from all available data.
In the patient based analysis, accuracies measured as "area-under-the-curve" (AUC) for (68)Ga-PSMA-PET, (99m)Tc-SPECT, (68)Ga-PSMA-PET/CT and (99m)Tc-SPECT/CT were 0.97-0.96, 0.86-0.83, 1.00 and 0.83, respectively (p<0.05) (ranges = optimistic vs. pessimistic view). Region based analysis resulted in the following sensitivities and specificities: 91.8-97.7%, 100-99.5% (PET); 61.2-70.6%, 99.8-98.3% (SPECT); 97.7%, 100% (PET/CT), 69.4% and 98.3% (SPECT/CT) (p<0.05). The amount of correct classifications of equivocal lesions by CT was significantly higher in PET (100%) compared to SPECT (52.4%) (p<0.05).
(68)Ga-PSMA-PET outperforms (99m)Tc-DPD-SPECT in detecting bone metastases in PC patients. Additional information from low-dose-CT resulted in a significant reduction in equivocal lesions in both modalities, however (68)Ga-PSMA-PET benefited most.
• Ga-PSMA-PET outperforms (99m) Tc-DPD-SPECT in skeletal staging in prostate cancer patients • Proportion of equivocal decisions was significantly reduced by CT-fusion in both modalities • Ga-PSMA-PET benefits more from CT information, compared to (99m) Tc-DPD-SPECT.